JERSEY CITY, N.J., Dec. 7 /PRNewswire/ -- Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that Ulrich Grau, Ph.D., President and Chief Executive Officer, will participate in the "Eyeing the Future of AMD" panel at the RBC Capital Markets Healthcare Conference in New York. The panel discussion will take place at 11:00 am ET on Thursday, December 14th, 2006, at the Westin New York at Times Square.
The presentation will be webcast live and may be accessed at http://www.wsw.com/webcast/rbc62/panel26. An archived version of the webcast will be available at the same location 30 days following the presentation.
About Lux Biosciences
Lux Biosciences is a privately held biotechnology company dedicated to the identification, optimization, development and commercialization of products for the treatment of ophthalmic diseases. The company's business strategy is characterized by:
-- A focus on compounds already marketed or with clinical proof-of-concept in non-ophthalmic indications that Lux will develop as unique, targeted therapies for corresponding ophthalmic diseases, with potentially greater efficacy and safety than existing treatments
-- A clinical-stage portfolio of projects including a next-generation calcineurin inhibitor that has potential in several ophthalmic diseases and, as such, represents a pipeline of product opportunities. LX211 is the oral dosage and is entering pivotal clinical testing in uveitis by early 2007. If successful, Lux expects the product will reach the market in 2009. Lux is advancing another project into pivotal clinical trials, namely LX201, a cyclosporine A eluting ocular implant designed to prevent rejection in corneal allograft patients.
-- A proprietary product enabling bio-erodable polymer technology that allows targeted delivery of Lux molecules to the eye
This strategy is being implemented by an experienced, execution-oriented management team that combines a history of achievement in drug development and commercialization with deep insight and scientific expertise in immunology and ophthalmology. More information on Lux Biosciences can be found at www.luxbio.com.
CONTACTS: Lux Biosciences Suda Communications (media) Ulrich Grau, Ph.D. Paul Kidwell +1 917-518-2875 +1 617-296-3854 ulrich.grau@luxbio.compaulkidwell@comcast.net
Lux Biosciences, Inc.CONTACT: Ulrich Grau, Ph.D. of Lux Biosciences, +1-917-518-2875,ulrich.grau@luxbio.com; or Paul Kidwell of Suda Communications - media,+1-617-296-3854, paulkidwell@comcast.net
